WMS 2022 symposium: Navigating the changing disease landscape: continuity of care in Duchenne muscular dystrophy
The best practice management and continuity of care in patients with Duchenne muscular dystrophy (DMD) was the focus of this symposium, presented at WMS 2022
Discover more about DMD, a rare, severe neuromuscular disease
Review the best practice management of DMD patients
Explore continuity of care for DMD patients
Examine real-world clinical data of patients with nonsense mutation DMD
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This symposium was developed and funded by PTC Therapeutics for WMS 2022.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300003 | February 2023
Sign in or register to access exclusive content on this site